ABSTRACT
Background: A few months after the COVID-19 pandemic onset, knowledge of SARS-CoV-2 infection and outcomes and treatments blew up. This paper aimed to evaluate the features of a Tuscany COVID-19 hospitalized cohort and to identify risk factors for COVID-19 severity. Methods: This retrospective observational COVID-19 cohort study (1 March 2020-1 March 2021) was conducted on patients ≥ 18 years old, admitted to Tuscany Hospital, and subjected to follow-up within 12 months after discharge. Patients were enrolled at Pisana, Senese and Careggi University Hospitals, and South East, North West, and Center Local Hospitals. Results: 2888 patients (M = 58.5%, mean age = 66.2 years) were enrolled, of whom 14.3% (N = 413) were admitted to an intensive care unit. Smokers were 25%, and overweight and obese 65%. The most used drugs were corticosteroids, antacids, antibiotics, and antithrombotics, all antiviral drugs, with slight differences between 2020 and 2021. A strong association was found between outcomes of evolution towards critical COVID-19 (non-invasive mechanical ventilation (NIV) and/or admission to intensive care) and smoking (RR = 4.91), ex-smoking (RR = 3.48), overweight (RR = 1.30), obese subjects (RR = 1.62), comorbidities (aRR = 1.38). The alteration of liver enzymes (aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyl transpeptidase) was associated with NIV (aOR = 2.28). Conclusions: Our cohort, characterized by patients with a mean age of 66.2 years, showed 65% of patients were overweight and obese. Smoking/ex-smoking, overweight/obesity, and other comorbidities were associated with COVID-19 adverse outcomes. The findings also demonstrated that alterations in liver enzymes were associated with worse outcomes.
ABSTRACT
AIMS: Although calculation of the global cardiovascular risk is strongly recommended, limited data are available regarding the use and the utility of this tool in clinical practice. We aimed at answering the following questions in the setting of Italian general practice: how many patients are evaluated via the cardiovascular risk algorithm; what are their characteristics; and what happens after their evaluation. METHODS: We used the Health Search/CSD Longitudinal Patient Database. The software used by about 800 participating GPs allows the calculation of the global cardiovascular risk in automatic. The following data were yearly extracted from the database within 2004-2008: age, sex, and recorded diagnosis of the main cardiovascular and other information encompassing smoking habits, blood pressure, total cholesterol, high density lipoprotein cholesterol (i.e., variables used to calculate cardiovascular risk), BMI, physical activity, triglycerides, glucose and creatinine; wherever available, current cardiovascular therapy and the automatically computed global cardiovascular risk were also extracted. RESULTS: In 2008, the observed population, aged 35-69 years, numbered 438â922 individuals; 78â617 (17.9%) had at least one calculation of cardiovascular risk; 20â181 patients were re-evaluated at least once: 61.1% among high-risk patients, 43.8% among moderate-risk patients, and 27.2% among low-risk patients. The level of cardiovascular risk measured at baseline increased in 6863 (34%), decreased in 11â791 (58.4%), and did not change in 1527 (7.6%) individuals. Overall, mean cardiovascular risk decreased over 4 years in 2.25% (SD 6.41%; Pâ<â0.01) of patients. CONCLUSION: The calculation of global cardiovascular risk is underused by GPs, who generally assign a higher priority to high-risk individuals. In addition, the use of this algorithm seems to favor a reduction of risk in moderate-risk and high-risk patients.
Subject(s)
Algorithms , Cardiovascular Diseases/epidemiology , Risk Assessment/methods , Adult , Aged , Blood Pressure , Cardiovascular Diseases/blood , Cholesterol, HDL/blood , Databases, Factual , Exercise , Female , Humans , Italy , Male , Middle Aged , Risk Factors , Triglycerides/bloodABSTRACT
UNLABELLED: This study was aimed to investigate the effects of computerized decision support system in improving the prescription of drugs for cardiovascular prevention. A total of 197 Italian general practitioners were randomly allocated to receive either the alerting computerized decision support system integrated into standard software (intervention arm) or the standard software alone (control arm). Data on 21230 patients with diabetes, 3956 with acute myocardial infarction, and 2158 with stroke were analysed. The proportion of patients prescribed with cardiovascular drugs and days of drug-drug interaction exposure were evaluated. Computerized decision support system significantly increased the proportion of patients with diabetes prescribed with antiplatelet drugs (intervention: +2.7% vs. CONTROL: +0.15%; p < 0.001) or lipidlowering drugs (+4.2% vs. +2.8%; p = 0.001). A statistically significant decrease in days of potential interactions has been observed only among patients with stroke (-1.2 vs. -0.5 days/person-year; p = 0.001). In conclusion, computerized decision support system significantly increased the use of recommended cardiovascular drugs in diabetic patients, but it did not influence the exposure to potential interactions.
Subject(s)
Cardiovascular Diseases/drug therapy , Decision Support Systems, Clinical , Drug Interactions , Drug Prescriptions/standards , Aged , Diabetes Mellitus, Type 2/therapy , Female , General Practice , Humans , Italy , Male , Myocardial Infarction/therapy , Software , Stroke/therapyABSTRACT
BACKGROUND: There are several guidelines dealing with the management of low back pain (LBP), but only few studies on the quality of care provided within General Practices as judged against those guidelines.The objective of this study is to analyse the management of LBP in Italian General Practice and compare it with guideline recommendations. METHODS: In this observational study, all patients visiting their General Practitioners (GPs) for treatment of LBP within a 8-week period were monitored for at least four weeks with regard to symptoms and diagnostic and therapeutic interventions. Management of LBP was judged by pre-defined quality indicators based on guideline recommendations. RESULTS: Twenty-five of 114 eligible GPs participated in the study, representing a total of 43,012 registered patients. Of the 475 patients complaining of LBP and monitored for four weeks, 55.8% were diagnosed as having acute lumbar pain, 13.5% chronic lumbar pain, 17.1% acute sciatica, and 12.6% chronic sciatica; 76.0% underwent no technical investigations, 21.7% underwent x-rays, 5.5% MRI and 4% CT scans; 20.4% were referred to secondary care; 93.3% of all patients received some medication. In those receiving a medication, in 88.3% it was an NSAID, in 6.3% Paracetamol, in 10.4% Paracetamol combined with Codeine, and in 9% a muscle relaxants. When physiotherapy was prescribed (17,1%), it was mostly massage. Hardly more than 50% of GPs (partially) followed locally established guidelines, while the remainder seemed not to follow guidelines at all. CONCLUSIONS: Our study reveals gross deviations of GP management of LBP from current guidelines and points to two different types of deviators: those who partially follow guidelines, and those who do not follow them at all. Further research should evaluate whether these two types of deviation are best addressed by different foci of education, i.e. on knowledge versus attitudes, respectively.
Subject(s)
General Practice/standards , Guideline Adherence , Low Back Pain/diagnosis , Practice Guidelines as Topic , Process Assessment, Health Care , Acute Pain/diagnosis , Acute Pain/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Analgesics, Opioid/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Chronic Pain/diagnosis , Chronic Pain/therapy , Cohort Studies , Female , Humans , Italy , Low Back Pain/therapy , Magnetic Resonance Imaging/statistics & numerical data , Male , Massage/statistics & numerical data , Middle Aged , Neuromuscular Agents/therapeutic use , Physical Therapy Modalities/statistics & numerical data , Prospective Studies , Quality Assurance, Health Care , Referral and Consultation/statistics & numerical data , Sciatica/diagnosis , Sciatica/therapy , Tomography, X-Ray Computed/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: Aspirin is recommended as preventive therapy in patients with cardiovascular diseases (CVD), diabetes mellitus, and high cardiovascular risk due to multiple risk factors. However, the benefits of aspirin might be affected by its inappropriate use. Real-life information on aspirin use is therefore needed as an audit tool aimed to maximize the benefits and minimize the risks. DESIGN: Retrospective cross-sectional and cohort study. METHODS: Primary care data were obtained from 400 Italian general practitioners (GPs) providing information to the Health Search/CDS Longitudinal Patients Database. Prevalence of use was assessed in individuals aged 18 years and older, registered in the GP's list at the beginning of the observation period (year 2005). As potential correlates of aspirin use, clinical and demographic variables were also recorded. Logistic regression analysis was conducted to assess the relationship between such covariates and aspirin use. Persistence to aspirin treatment was examined among newly prescribed aspirin users during the years 2000-04. RESULTS: On a total sample of 540,984 patients, 45,271 (8.3%) were prescribed at least once with aspirin. On 35,473 patients with previous CVD, 51.7% were treated with aspirin, whereas only 15.2% of 151,526 eligible patients free of CVD received an aspirin prescription. In primary prevention, prevalence of aspirin use was significantly associated with the increased number of cardiovascular risk factors either among diabetic (p < 0.001) or non-diabetic (p < 0.001) patients. A negative association has been observed among patients with contraindication to aspirin use. Only 23.4% of patients at 1 year and 12.2% at 2 years remained persistent with aspirin use, although most of first-time users reported an intermittent use. CONCLUSION: Underuse and discontinuation of aspirin treatment is common among eligible patients. Increased cardiovascular risk only partially influences aspirin management. An effort aimed to improve appropriate aspirin use is likely to provide major benefits.
Subject(s)
Ambulatory Care/statistics & numerical data , Aspirin/therapeutic use , Cardiovascular Agents/therapeutic use , Cardiovascular Diseases/drug therapy , Practice Patterns, Physicians'/statistics & numerical data , Preventive Health Services/standards , Primary Health Care/statistics & numerical data , Adult , Aged , Aspirin/adverse effects , Cardiovascular Agents/adverse effects , Cross-Sectional Studies , Drug Prescriptions/statistics & numerical data , Drug Utilization/statistics & numerical data , Female , Guideline Adherence , Health Care Surveys , Humans , Inappropriate Prescribing/statistics & numerical data , Italy , Logistic Models , Male , Middle Aged , Odds Ratio , Practice Guidelines as Topic , Proportional Hazards Models , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Young AdultABSTRACT
BACKGROUND: Fluoroquinolones are widely used both in primary care and in hospital settings. Since the last comparison performed in Italy on the safety profiles of different fluoroquinolones, a new molecule, prulifloxacin, has been introduced into the market and several warnings concerning this class of drugs have been released. The aim of this study was to reassess the safety profiles of fluoroquinolones using the database of the Italian Interregional Group of Pharmacovigilance (IGP) and the administrative data of fluoroquinolone prescriptions. METHODS: All adverse drug reactions (ADRs) reported in four Italian regions (Lombardy, Veneto, Emilia Romagna and Tuscany) were retrieved from the IGP database. Consumption data (defined daily dose [DDD]/1000 inhabitants/day) were used as denominators. Both single reports and all ADRs (classified by System Organ Classes and MedDRA Preferred Term [PT]) due to fluoroquinolones were considered as numerators of each analysis, comparing two periods (2005 vs 2006). All fluoroquinolones with at least ten reports per year were included in the analysis. RESULTS: On the basis of 272 reports (532 single ADRs or PTs), patients did not show any statistically significant differences between 2005 and 2006 in terms of sex, age and number of concurrent medications. After adjustment for drug consumption, moxifloxacin showed the highest reporting rate (84.6 reports/DDD/1000 inhabitants/day; 15.4 serious reports/DDD/1000 inhabitants/day) followed by prulifloxacin (72.2; 22.2 serious) and levofloxacin (55.3; 30.6 serious) in 2005. An increment of ADR/report rates was observed over the 2 years for all fluoroquinolones except prulifloxacin, which had the lowest ADR reporting rate in 2006 (25.0; 12.5 serious). In 2006, the rate of serious ADRs associated with prulifloxacin was lower than with ciprofloxacin, while in 2005 serious events were almost equal for both compounds (55.6 vs 47.6 serious ADRs/DDD/1000 inhabitants/day). Ciprofloxacin showed the highest proportion of cutaneous PTs (e.g. rash, exanthema). Tendinopathies were mainly due to levofloxacin. CONCLUSIONS: These data suggest that different fluoroquinolones are characterized by different rates and types of ADRs. Among them, prulifloxacin was associated with more ADRs than other fluoroquinolones in 2005 but with fewer ADRs in 2006, when its consumption increased. Although these findings may represent an encouraging perspective towards a more appropriate use of fluoroquinolones because of their individual safety profiles, further pharmacoepidemiological studies must be performed to substantiate these results.
Subject(s)
Adverse Drug Reaction Reporting Systems/statistics & numerical data , Anti-Infective Agents/adverse effects , Databases, Factual/statistics & numerical data , Fluoroquinolones/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Infective Agents/administration & dosage , Child , Female , Fluoroquinolones/administration & dosage , Humans , Italy , Male , Middle Aged , Young AdultABSTRACT
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with many comorbidities, but the percentage of COPD patients who develop comorbidities has not been clearly defined. OBJECTIVES: We aimed to examine the relationship between COPD and comorbidities using information obtained from the Health Search Database (HSD) owned by the Italian College of General Practitioners (SIMG), which stores information on about 1.5% of the total Italian population served by general practitioners. METHODS: We conducted a population-based retrospective study using information obtained from the HSD. The software system used codes all the diagnostic records using the 9th Revision of the International Classification of Diseases. RESULTS: Compared to the non-COPD people, COPD patients were at increased risk for cardiovascular events [ischemic heart disease (6.9% in the general population vs. 13.6% in COPD patients), cardiac arrhythmia (6.6% in the general population vs. 15.9% in COPD patients), heart failure (2.0% in the general population vs. 7.9% in COPD patients), and other forms of heart disease (10.7% in the general population vs. 23.1% in COPD patients); with a higher impact of COPD in the elderly]; non-psychotic mental disorders, including depressive disorders (29.1% in the general population vs. 41.6% in COPD patients; with a higher impact of COPD on women aged <75 years); diabetes mellitus (10.5% in the general population vs. 18.7% in COPD patients); osteoporosis (10.8% in the general population vs. 14.8% in COPD patients), with a higher impact of COPD on women aged <75 years, and malignant pulmonary neoplasms (0.4% in the general population vs. 1.9% in COPD patients). CONCLUSIONS: Our results indicate that COPD is a risk factor for these comorbid conditions.
Subject(s)
Comorbidity , Pulmonary Disease, Chronic Obstructive/epidemiology , Aged , Aged, 80 and over , Female , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , Retrospective StudiesABSTRACT
BACKGROUND: Nonadherence to antihypertensive treatment is a common problem in cardiovascular prevention and may influence prognosis. We explored predictors of adherence to antihypertensive treatment and the association of adherence with acute cardiovascular events. METHODS AND RESULTS: Using data obtained from 400 Italian primary care physicians providing information to the Health Search/Thales Database, we selected 18,806 newly diagnosed hypertensive patients >or=35 years of age during the years 2000 to 2001. Subjects included were newly treated for hypertension and initially free of cardiovascular diseases. Patient adherence was subdivided a priori into 3 categories-high (proportion of days covered, >or=80%), intermediate (proportion of days covered, 40% to 79%), and low (proportion of days covered, Subject(s)
Antihypertensive Agents/therapeutic use
, Cardiovascular Diseases/prevention & control
, Hypertension/drug therapy
, Hypertension/psychology
, Patient Compliance
, Aged
, Cardiovascular Diseases/epidemiology
, Cardiovascular Diseases/etiology
, Cohort Studies
, Databases, Factual
, Diabetes Complications
, Drug Therapy, Combination
, Dyslipidemias/complications
, Female
, Humans
, Hypertension/complications
, Incidence
, Male
, Middle Aged
, Obesity/complications
ABSTRACT
Using a general practice research database with general practitioner (GP) clinical records, it has been observed that among the 617,280 subjects registered with 400 Italian GPs, 15,229 (2.47%) patients were suffering from chronic obstructive pulmonary disease (COPD). Of these, 67.7% had a chest radiograph at least once in a period of 10 years (1997-2006), while in the same period only 31.9% had a spirometry, 29.9% had a visit to a specialist, and 0.94% had a visit to an allergologist. From 1997 to 2006, 7.5% of patients with COPD, especially the oldest ones, were hospitalized at least once for the disease, although 44.0% of all patients with COPD were hospitalized for other pathologies. With regard to treatment, in 2006, 10,936 (71.1%) of COPD patients received at least one drug for their disease (drugs classified within the R03 therapeutic pharmacological subgroup of the Anatomical Therapeutic Chemical Classification). In particular, salmeterol/fluticasone was prescribed 6441 times, tiotropium 4962, theophylline 3142, beclomethasone 2853, salbutamol 2256, formoterol 2191, salbutamol/beclomethasone 2129, oxitropium 1802 and formoterol/budesonide 1741 times. Based on these findings, the level of COPD management in Italy seems to fall short of recommended international COPD guidelines. In particular, it appears that GPs usually prescribe treatment without the use of spirometry, and/or without taking into account the severity of airway obstruction. It must also be noted that, in general, patients with COPD are undertreated.
Subject(s)
Primary Health Care/statistics & numerical data , Pulmonary Disease, Chronic Obstructive/therapy , Administration, Inhalation , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Adult , Aged , Anti-Asthmatic Agents/therapeutic use , Bronchodilator Agents/therapeutic use , Child , Child, Preschool , Cholinergic Antagonists/therapeutic use , Drug Therapy, Combination , Female , Hospitalization/statistics & numerical data , Humans , Infant , Infant, Newborn , Italy/epidemiology , Male , Middle Aged , Practice Guidelines as Topic , Pulmonary Disease, Chronic Obstructive/diagnostic imaging , Pulmonary Disease, Chronic Obstructive/drug therapy , Radiography , Referral and Consultation/statistics & numerical data , Retrospective Studies , Smoking/epidemiology , Spirometry/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: Sudden cardiac death (SCD) is a major cause of death in western countries, with coronary heart disease (CHD) being the basis of over 70% of SCD. Incidence in high-CHD risk countries has already been studied, but this information is not available for Mediterranean low-CHD risk countries. Incidence is of paramount importance when cost-effectiveness rate of actions against SCD must be estimated. METHODS: We estimated the incidence of SCD and its potential risk associated with clinical variables, by a means of a case-control study in a general practice setting. The enrolled general practitioners (GPs) provided data about the total number of their patients, and identified all their patients who suffered an out-of-hospital SCD during the previous 365 days. Two age-matched and gender-matched controls visiting GPs office after the SCD selection were also selected. We used a structured questionnaire to obtain information about potential risk factors for SCD. Covariates that were univariately associated with SCD were included in the multivariate regression analyses. RESULTS: In a population of 297 340 (age greater than 14 years), a total of 230 cases were identified (0.77 per 1000 individuals), mostly occurring at home and among persons with known high cardiovascular risk. In the multivariate analysis only CHD (OR: 1.67; 95% CI: 1.09-2.58), arrhythmia (OR: 2.2; 95% CI: 1.3-3.9), obesity (OR: 2.3; 95% CI: 1.5-3.6), alcohol abuse (OR: 1.8; 95% CI: 1.2-2.7), and family history of CHD (OR 3.1; 95% CI: 1.8-5.3) resulted in a significant association with SCD. CONCLUSIONS: The incidence of SCD in Italy is lower than that reported in high-CHD risk population, most of the cases occurring at home and among persons with known high cardiovascular risk. Implementing recommendations for these patients seems to be the most effective strategy to reduce the incidence of SCD.
Subject(s)
Death, Sudden, Cardiac/epidemiology , Adolescent , Adult , Aged , Alcoholism/complications , Arrhythmias, Cardiac/complications , Case-Control Studies , Coronary Disease/genetics , Coronary Disease/mortality , Family Practice , Female , Humans , Italy/epidemiology , Male , Middle Aged , Multivariate Analysis , Obesity/complications , Risk Factors , Surveys and QuestionnairesABSTRACT
The purpose of the study was to investigate the risk of stroke with typical and atypical anti-psychotics in elderly subjects, weighting for a number of known risk factors, including dementia. Data were retrospectively drawn from the primary care setting from the Health Search Database, which stores information on about 1.5% of the total Italian population served by general practitioners. All elderly patients (65+ years) prescribed an anti-psychotic in monotherapy from January 2000 to June 2003 were selected for the study. A cohort of patients not exposed to anti-psychotics was taken from the same database. Subjects who had previously had a stroke were excluded. The main outcome measure was the incidence of first-ever stroke during exposure to an anti-psychotic.The sample included non-users (69,939), users of atypicals (599), butyrophenones (749), phenotiazines (907) and substituted benzamides (1,968). The crude incidence of stroke in subjects not exposed to anti-psychotics was 12.0/1000 person-years. Risk was significantly higher for those on butyrophenones (47.1/1000), phenotiazines (72.7/1000) and in the atypical anti-psychotic group (47.4/1000). Substituted benzamides had an almost significant higher risk (25.0/1000). Cox regression modelling, weighting for demographic and clinical variables with non-users as the reference group, showed that the risk for stroke was 5.79 times for phenotiazines, 3.55 times for butyrophenones, and 2.46 times for atypicals. Clinicians should be cautious in prescribing phenotiazines and butyrophenones in elderly patients, since the risk for stroke would seem comparable or even greater than with atypicals.
Subject(s)
Antipsychotic Agents/adverse effects , Stroke/chemically induced , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Incidence , Male , Multivariate Analysis , Retrospective Studies , Risk , Stroke/epidemiologyABSTRACT
PURPOSE: To determine the prevalence of concomitant use of drugs potentially responsible for interactions among itraconazole and fluconazole users in general practice. METHODS: During the years 1999-2002, we obtained information from the 'Health Search Database', (HSD) an Italian general practice research database. Among a total sample of 457 672 eligible patients, we included those aged >16 years, and whose diagnoses could be classified as mycosis. Itraconazole and fluconazole users were then selected. A potentially drug-drug interaction (DDI) occurred when the use of concomitant drugs were recorded within +/-30 days from the date of the first azoles prescription. Interacting drugs were classified according to the summary of product characteristics (SPC) as provided by the Italian Pharmaceutical Repertory (REFI). RESULTS: From 18 323 cases of mycosis, we selected 4843 itraconazole and 1446 fluconazole users. Potentially interacting drugs were prescribed in 8.7% of itraconazole and 6.1% of fluconazole users. For itraconazole, calcium channel blockers were the most common interacting drugs (3.3%), followed by statins (1.7%) and clarithromycin (1.3%), whereas gestoden + ethynylestradiol (2.5%) and benzodiazepines (1.8%) resulted as the most common interacting drugs among fluconazole users. CONCLUSION: Data indicate a relevant prevalence of concomitant use of medications potentially leading to drug interactions among azoles users. Because of the wide use of these medications in general practice, they should be used with clinical monitoring in view of their known side effects as well as their potential risk for drug interaction.
Subject(s)
Antifungal Agents/therapeutic use , Family Practice/statistics & numerical data , Fluconazole/therapeutic use , Itraconazole/therapeutic use , Mycoses/drug therapy , Polypharmacy , Practice Patterns, Physicians'/statistics & numerical data , Adolescent , Adult , Aged , Databases as Topic/statistics & numerical data , Drug Interactions , Drug Prescriptions/statistics & numerical data , Drug Utilization/statistics & numerical data , Female , Humans , Italy/epidemiology , Male , Middle Aged , Mycoses/epidemiology , Odds Ratio , Risk Assessment , Time FactorsABSTRACT
PURPOSE: To verify General Practitioners (GPs) compliance to the recommended laboratory monitoring for statin users. METHODS: A retrospective study was conducted collecting data from the database of Italian College of General Practitioners, named Health Search; all the participant physicians used an automatic pop-up which reminds them to periodically check liver enzyme levels in statin-users. We examined the patients who received their first statin prescription from 29 November 1999 to 28 November, 2002. CPK, ASL, AST, and creatinine values recorded before and after the first prescription were evaluated. The minimum and maximum observation time before and after prescription were 6 and 42 months, respectively. The prevalence of laboratory monitoring prescribed by GPs was calculated at baseline and during follow-up for all patients and for the subgroup of high-risk patients. RESULTS: We identified 14 120 first-ever statin users (male 47.4%). CPK, AST, ALT and creatinine tests were prescribed at least once at baseline in 8.5%, 53.9%, 50.9%, and 64.0% of patients, respectively; during the follow-up 37.8%, 64.4%, 60.3%, and 61.5% of patient received the same tests prescriptions, respectively. No difference between high-risk and non-high-risk patients was observed. During the follow-up enzyme levels greater than three times the upper normal limit were recorded in 0.4%, 0.1%, 0.1%, and 0.3% of subjects for CPK, AST, ALT and creatinine, respectively. CONCLUSION: Adherence to the recommended laboratory monitoring for statin users is very low among Italian GPs, even for high-risk patients. Automatic reminders which pop-up whenever statins are prescribed are ineffective.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Primary Health Care , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Creatine Kinase/blood , Female , Humans , Lipids/blood , Male , Middle AgedABSTRACT
UNLABELLED: BACKGROUND; Heart failure (HF) represents an important health issue in western countries, especially for the elderly, frail population. A number of HF patients must usually be assisted at home. No information is available about the usual care of HF patients in Italy. The aim of this study was to describe the characteristics of HF patients receiving homecare in the Italian general practice. METHODS: A questionnaire was sent to 320 general practitioners (GPs) involved in the Health Search project. Among these, 148 (46.2%) answered and 376 home-ridden HF patients (60.3% women, median age 85 years) were identified. RESULTS: 257 (57%) patients were in NYHA class III or IV. Multiple relevant concomitant diseases occurred in 326 (86.7%) subjects. Only 140 (37.2%) patients were able to take their pills without any help; caregivers, mainly family members, were required 24 hours a day in 78.7% of cases. The length of homecare was > 1 year in 84.5% of cases. CONCLUSIONS: According to our data, thousands of HF patients are usually assisted at home for long periods in Italy. This is a very old group of subjects with heavy co-morbidity and a high need for continuous, prolonged assistance. Studies specifically aimed at the care of HF patients are needed.
Subject(s)
Heart Failure/therapy , Home Care Services/statistics & numerical data , Aged , Aged, 80 and over , Female , Humans , Italy , Male , Middle Aged , Surveys and QuestionnairesABSTRACT
BACKGROUND: Benzodiazepines (BDZs) are among the most commonly prescribed drugs in the elderly and their use is often too prolonged according to current international guidelines. METHODS: We investigated the pattern of use of BDZs among 65- to 84-year-old attenders at 40 Italian primary care practices who answered positively in a questionnaire on the use of anxiolytic/hypnotic drugs and successfully completed the PRIME-MD questionnaire. The survey lasted 6 months, from February to July 2001. RESULTS: Of the 1,156 subjects who completed the PRIME-MD, 748 subjects were positive for at least one psychiatric diagnosis. A depressive disorder was present in 36.5% of all PRIME-MD completers and in about one-third of cases represented by major depression, whereas anxiety disorders, somatoform disorders and alcohol abuse accounted for 18.2%, 8.1% and 1.7% of all PRIME-MD completers, respectively. Most patients were first prescribed BDZs by their General Practitioners (GPs) for each diagnostic group. However, patients with pure anxiety started BDZ treatment during hospitalisation more often (19.7%) than patients with depressive disorders (13.7 %). Moreover, patients with comorbid anxiety and depressive disorders (CADD) were most likely to receive their first BDZ prescription from a psychiatrist (15.7 %). Sleep disturbances were present in at least 50% of cases (and up to 86 %) in each diagnostic group. About 75% of prescriptions concerned anxiolytic BDZ or medium/long-acting BDZ. Most patients with anxiety, CADD and depression used night-time BDZ (65.2%, 56.9 % and 60.5%, respectively). The prevalence of chronic use of BDZs was equally high in all categories of psychiatric disorder (about 90 % for each), showing that the vast majority of patients, irrespective of the diagnosis, had been using BDZs for years. CONCLUSIONS: BDZs are widely prescribed for elderly people by their GPs, often for a considerable length of time. The evidence that many BDZ consumers suffer from a depressive or an anxiety disorder, or both, could be a starting point for encouraging a rational prescription in accordance with international guidelines.
Subject(s)
Benzodiazepines/adverse effects , Mental Disorders/chemically induced , Mental Disorders/epidemiology , Primary Health Care/statistics & numerical data , Substance-Related Disorders/epidemiology , Substance-Related Disorders/rehabilitation , Surveys and Questionnaires , Adult , Aged , Aged, 80 and over , Female , Humans , Italy/epidemiology , Male , Mental Disorders/diagnosis , Middle AgedABSTRACT
BACKGROUND: Stroke represents worldwide the second and seventh cause of death and invalidity, respectively. Patients with ischaemic stroke or transitory ischaemic attack (TIA) are at high risk of recurrence, therefore requiring intensive treatment. Hypercholesterolaemia is a modifiable risk factor for stroke. The general practitioners attitude towards detection and treatment of dyslipidaemia among patients with stroke or TIA in Italy is unknown; we therefore aimed to address this issue taking advantage of the database of The Italian College of General Practitioners. METHODS: Prevalence of the monitored factors (lipid levels, statin prescription, and lipid level control with hypolipidaemic agents prescription) were analysed on a patient population of 465 061. RESULTS: A total of 2555 (49% women and 51% men) patients with a diagnosis of stroke and 2755 patients (52% women and 48% men) with a diagnosis of TIA were included in the study. Total plasma cholesterol (TC) was reported in more than 60% of the patients and low-density lipoprotein cholesterol (LDLc) and high-density lipoprotein cholesterol (HDLc) in less than half. Total plasma cholesterol and LDLc were controlled in 70.3 and 72.8% of the patients, respectively. The percentage of controlled patients decreased to 64% when both LDLc and TC were considered. Statins and fibrates were prescribed in a small proportion of patients (16.9 and 3.5%, respectively). An acceptable control of blood lipids was achieved in a majority of those patients (60.2%). However a relatively large number of patients (646) with high plasma lipids remained untreated. CONCLUSIONS: Monitoring and intervention strategies on plasma lipid levels in patients with a diagnosis of stroke or TIA need to be improved.
Subject(s)
Hypercholesterolemia/prevention & control , Ischemic Attack, Transient/epidemiology , Ischemic Attack, Transient/prevention & control , Stroke/epidemiology , Stroke/prevention & control , Age Distribution , Aged , Aged, 80 and over , Analysis of Variance , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cross-Sectional Studies , Family Practice , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/drug therapy , Incidence , Italy/epidemiology , Male , Middle Aged , Probability , Registries , Risk Assessment , Sex Distribution , Survival AnalysisABSTRACT
BACKGROUND: The aim of this study was to compare the prevalence of angina pectoris (AP) using self-reported information and primary care databases. METHODS: A comparison between the prevalence of AP in 730,586 subjects from the Health Search Database (HSD) and 119,799 individuals from a Health Interview Survey (HIS) was performed. The age-specific prevalence was calculated by dividing the detected cases by the total number of individuals in each age group. The age-standardized prevalence was estimated by direct standardization performed using the Italian standard population. RESULTS: The HSD reported a higher crude prevalence of AP than the HIS, both in males (1374/100,000 vs 1006/100,000) and females (1449/100,000 vs 1007/100,000). In the HSD the age-specific prevalence was lower for patients aged <65 years, whilst higher estimates were reported for older patients. Age standardization slightly reduced the prevalence in both samples, although the HSD always reported higher estimates. CONCLUSIONS: Prescription data from general practice databases may be a valid, simple, and cost-effective method to evaluate and serially monitor the prevalence of AP.
Subject(s)
Angina Pectoris/epidemiology , Databases, Factual/statistics & numerical data , Electronic Data Processing/economics , Family Practice/statistics & numerical data , Adolescent , Adult , Age Distribution , Aged , Cost-Benefit Analysis , Databases, Factual/economics , Databases, Factual/standards , Family Practice/economics , Female , Health Surveys , Humans , Italy/epidemiology , Male , Middle Aged , Prevalence , Sex DistributionABSTRACT
OBJECTIVES: To assess the antipsychotic use and the prevalence/incidence of antipsychotic drug users in Italy during the years 1999-2002. To estimate the persistence with antipsychotic medications, and to measure their off-label use. METHODS: We selected 465,061 individuals registered by June 2002 in the lists of 320 general practitioners, homogeneously distributed throughout Italy, from the Health Search Database. We measured the antipsychotic drug consumption, calculated as defined daily dose (DDD) per 1000 inhabitants per day. We also calculated the number of individuals receiving at least one antipsychotic prescription, to estimate the annual prevalence and incidence of antipsychotic users. Among incident users, we evaluated the percentage of patients adherent to drug label indications and the average duration of treatment, estimated as medical possession ratio (MPR). RESULTS: Atypical antipsychotic use has continuously increased from 1999 to 2002. Women, older people and patients affected by psychotic disorders other than schizophrenia were seen to be more likely to receive antipsychotic prescriptions. Persistence with atypical drug treatment (MPR=0.213 in 2002) appeared longer than that of typical drugs (0.169). The percentage of patients adherent to drug label indications was significantly higher among typical antipsychotic users (P<0.001). The most common off-label use for atypical drug was senile dementia. CONCLUSION: Atypical drug use has been continuously expanding over the years 1999-2002, particularly in older people with dementia. The rapidly increasing use of this new class of antipsychotics highlights the need for a better evaluation regarding their safety profile and a better definition of their role in psychiatric treatments.
Subject(s)
Antipsychotic Agents/therapeutic use , Family Practice , Mental Disorders/drug therapy , Practice Patterns, Physicians'/trends , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Databases, Factual , Female , Humans , International Classification of Diseases , Italy/epidemiology , Male , Mental Disorders/classification , Mental Disorders/epidemiology , Middle Aged , Patient Compliance , Pharmacoepidemiology , Prevalence , Sex DistributionABSTRACT
OBJECTIVE: To describe a database used in general practice by analysing the characteristics of the physicians providing the data and the completeness of the data recording on the basis of the indicators of interest (smoking habits, weight, height, and the prevalence of hypertension). DESIGN: Descriptive study and multiple linear regression analysis of the relationships between structural variables and outcomes. SETTING: General practitioners (GPs) belonging to the Italian Society of General Medicine (SIMG), and enrolled in Health Search (HS). POPULATION: Six hundred and ninety-five voluntarily enrolled GPs and their patients. PRINCIPAL OUTCOMES: Descriptive statistics (mean and median values, standard deviation, frequencies) concerning the general characteristics of the GPs, the ways in which they connect to the network and their use of the clinical data management software, and epidemiological measures concerning the prevalence of hypertension among their patients, and the recording of weight, height and tobacco smoking habits. RESULTS: The geographic distribution of the GPs is homogeneous: 317 in Northern Italy (12.52 physicians per 10(6) patients), 134 in Central Italy (12.30 physicians per 10(6) patients) and 244 in Southern Italy and the Islands (11.89 physicians per 10(6) patients). Five hundred and ninety-five (85.6%) are males; their mean age is 46.7 years (SD +/- 3.8); the mean number of patients per physician is 1128; 69% have at least one post-graduate specialisation; 49% practise alone; and they work for a mean of 30 hours per week (SD +/- 13). Five hundred and fifty-three GPs were actually connected to the network as of January 2003. The data relating to the years 2000-2001 show an increase in the number of connected physicians (34 in 2000 and 261 in 2001) and in the number of connections (a median of 12 in 2000 and 17 in 2001). The GPs contact more than 80% of their patients every year. The frequency of the recording of data concerning smoking habits, weight and height increases in proportion with the frequency of connections. The prevalence of hypertension among the patients included in the survey is 5.4%. Multiple regression analysis showed that the variability in the prevalence of hypertension was not influenced by the frequency of PC use but by the different structure of the age classes of the patients. CONCLUSIONS: This study of the variables relating to GPs, their clinical practices, and their use of computerised records (examined by means of the chosen indicators) shows that the regular and complete recording of the principal data of health interest is feasible insofar as it is not biased by the characteristics of the GPs, and advantageous. The construction of the database therefore represents a first step towards the initiation of routine research into general practice in Italy.
Subject(s)
Databases, Factual , Family Practice , Biomedical Research , Italy , Societies, MedicalABSTRACT
BACKGROUND: Oral anticoagulants (OAs) are recommended for many clinical problems and their use requires organised and knowledgeable medical support. Up to our knowledge, there is no data about both the reasons of treatment among OAs' users and the number of patients prescribed with OAs in Italy. OBJECTIVES: To describe the OA use, and the reasons of prescribing among Italian General Practitioners. METHODS: We used the Health Search Database owned by the Italian College of General Practitioners to identify the clinical records of patients > or =20 years who had at least one prescription of OAs during the year 2002. RESULTS: Among a study population of 448,495 patients, 3,649 subjects (0.81%) had received at least one OAs prescription. Applying such a proportion to the overall Italian population, on the basis of data from Italian Office for National Statistics (ISTAT), we estimated that 376,882 patients would have used OAs during the year 2002 in Italy. The most frequent clinical problem related to the use of OAs was atrial fibrillation (45.6%), followed by cardiac valve disease (14.6%), deep vein thrombosis (12.2%) and peripheral artery embolism (7.7%). CONCLUSIONS: Approximately 370,000 patients are prescribed with OAs in Italy and for more than 50% of them life-long therapy is recommended. Atrial fibrillation is the most frequent reason for prescription.